Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Type C Meeting Timings

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 13, 2024 1:14pm

139 Views

Post# 35987535

RE:RE:RE:Type C Meeting Timings

Type C Meeting -

" Type C meeting is any meeting other than a Type A, Type B, Type B (EOP), Type D, or INTERACT meeting regarding the development and review of a product, including meetings to facilitate early consultations on the use of a biomarker as a new surrogate endpoint that has never been previously used as the primary basis for product approval in the proposed context of use._ as per FDA Draft Guidance dated September 2023 (see link below)

https://www.fda.gov/media/172311/download

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?